Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 53, Issue 1, 2002, Pages 29-35

  Sawicki, W ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Controlled release; First pass effect; Floating pellet; Norverapamil; Oral bioavailability; Pharmacokinetics; Verapamil

Indexed keywords

BICARBONATE; CITRIC ACID TRIETHYL ESTER; EUDRAGIT; GELATIN; LACTOSE; MICROCRYSTALLINE CELLULOSE; NORVERAPAMIL; POVIDONE; STAVERAN; TALC; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; MALE; NORMAL HUMAN; SUSTAINED RELEASE PREPARATION; TABLET;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CALCIUM CHANNEL BLOCKERS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; FEMALE; HUMANS; MALE; SEX FACTORS; STATISTICS, NONPARAMETRIC; TABLETS; VERAPAMIL;

EID: 0036138883     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(01)00189-8     Document Type: Article

References (33)

1. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms
2. Assessment of disintegration and dissolution of dosage forms in vivo using gamma scintigraphy
3. The effect of capsule size and density on transit through the proximal colon
4. Clinical pharmacokinetics of vasodilators
5. The effects of age and gender on the stereoselective pharmacokinetics of verapamil
6. Simultaneous first-order and capacity-limited elimination kinetics after oral administration of verapamil
7. Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy
8. Model of a buccal drug form with verapamil. Part I. Preparation and in vitro release
9. Influence of polyoxyethylene-10-oleylether on in vitro verapamil hydrochloride penetration through mucous membrane from a model buccal drug formulation
10. Physico-chemical stability of controlled-release solid dispersion granules containing verapamil HCL as active substance
11. A method of obtaining floating tablets with verapamil
12. A dry granulation method of obtaining floating granules with verapamil
13. A validated method for the determination of verapamil and norverapamil in human plasma
14. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards
15. Plasma concentrations of S-verapamil after single doses of two different galenic formulation of racemic verapamil
16. The hepatic first-pass metabolism of problematic drugs
17. Tableting of coated pellets
18. Realization of the idea of multiparticulate dosage form
19. Gastroretentive dosage forms
20. Film coatings
21. Influence of plasticizers on the mechanical properties of pellets containing Eudragit RS 30 D
22. In vitro performance of floating sustained-release capsule of verapamil
23. Influence of time of administration on verapamil pharmacokinetics
24. In vitro and in vivo studies of sustained release floating dosage forms containing salbutamol sulfate
25. Intragastric behavior and absorption kinetics of a normal and 'floating' modified-release capsule of isradipine under fasted and fed conditions
26. Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers
27. Comparative bioavailability of verapamil from rapidly absorbed and slow release preparations
28. In vitro drug release testing
29. Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog
30. Pharmacokinetics of verapamil from an osmotic system with delayed onset
31. Faster clearance of sustained release verapamil in men versus woman: Continuing observations on sex-specific differences after oral administration of verapamil
32. Comparative pharmacokinetic study of floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol
33. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy